Abstract
Background Safety and toxicity data for nebulised tobramycin are mainly derived from use of the Pari LC® Plus nebuliser, yet many centres are now using advanced nebulisers, such as the eFlow®. Methods Ten children (ages 2–16 years) receiving 300 mg TOBI® via eFlow® for clinical reasons participated. Serum tobramycin levels were obtained 1 h post nebulisation. Nine provided samples for urinary NAG, and 10 underwent audiology. Results Tobramycin levels were > 1 mg/L in 3 children (maximum 3.8, 2 children aged 2 years). Urine NAG/creatinine levels were raised (> 0.94 μmol/min/mmol) in 5 children, 1 of these had a tobramycin level of > 1 mg/L. One patient had high frequency hearing loss. Conclusion Serum tobramycin levels over 1 mg/L can occur 1 h post 300 mg TOBI® delivered by eFlow®. Raised urinary NAG levels suggest that some children may have some associated early renal toxicity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
